What is the share price of Laurus Labs Ltd (LAURUSLABS) today?
The share price of LAURUSLABS as on 17th April 2025 is ₹628.05. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Laurus Labs Ltd (LAURUSLABS) share?
The past returns of Laurus Labs Ltd (LAURUSLABS) share are- Past 1 week: 8.62%
- Past 1 month: 7.31%
- Past 3 months: 10.61%
- Past 6 months: 32.18%
- Past 1 year: 45.58%
- Past 3 years: 4.18%
- Past 5 years: 669.20%
What are the peers or stocks similar to Laurus Labs Ltd (LAURUSLABS)?
The peers or stocks similar to Laurus Labs Ltd (LAURUSLABS) include:What is the dividend yield % of Laurus Labs Ltd (LAURUSLABS) share?
The current dividend yield of Laurus Labs Ltd (LAURUSLABS) is 0.13.What is the market cap of Laurus Labs Ltd (LAURUSLABS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Laurus Labs Ltd (LAURUSLABS) is ₹33785.84 Cr as of 17th April 2025.What is the 52 week high and low of Laurus Labs Ltd (LAURUSLABS) share?
The 52-week high of Laurus Labs Ltd (LAURUSLABS) is ₹646.20 and the 52-week low is ₹385.45.What is the PE and PB ratio of Laurus Labs Ltd (LAURUSLABS) stock?
The P/E (price-to-earnings) ratio of Laurus Labs Ltd (LAURUSLABS) is 210.44. The P/B (price-to-book) ratio is 8.21.Which sector does Laurus Labs Ltd (LAURUSLABS) belong to?
Laurus Labs Ltd (LAURUSLABS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Laurus Labs Ltd (LAURUSLABS) shares?
You can directly buy Laurus Labs Ltd (LAURUSLABS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Laurus Labs Ltd
LAURUSLABS Share Price
LAURUSLABS Share Price Chart
LAURUSLABS Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
LAURUSLABS Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
168.71 | 8.21 | 0.13% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
49.39 | 6.29 | 0.54% |
LAURUSLABS Analyst Ratings & Forecast
Detailed Forecast from 11 analysts
Price Upside
Earnings Growth
Rev. Growth
LAURUSLABS Company Profile
Laurus Labs Private Ltd is a research and development pharmaceutical company which manufactures active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Investor Presentation
View olderLAURUSLABS Similar Stocks (Peers)
Compare with peersLAURUSLABS Sentiment Analysis
LAURUSLABS Stock Summary · January 2025
Laurus Labs demonstrated robust revenue growth in Q3 FY25, driven by strong demand in the CDMO sector, despite challenges in the ARV business, which saw a 7% decline in revenue. The company is strategically enhancing its manufacturing capabilities, particularly in complex APIs and precision fermentation, while maintaining healthy gross margins above 50%. Management remains optimistic about future growth, supported by a diverse product pipeline and significant investments in R&D and new facilities. Although the ARV segment faces short-term challenges, a solid order book and ongoing collaborations with major pharmaceutical partners position Laurus for long-term success. Overall, the outlook reflects confidence in navigating current market dynamics while capitalizing on emerging opportunities.
Key Points on Lauruslabs Stock
LAURUSLABS Stock Growth Drivers
7Strong Performance in CDMO Business
Laurus Labs has demonstrated significant achievements in its Contract Development and Manufacturing Organization (CDMO) business,
Healthy Financial Metrics
The company reported strong financial results, with Q3 revenues reaching INR 1,415 crores, an 18%
LAURUSLABS Stock Challenges
7Decline in ARV API Business
Laurus Labs reported a 3% decline in their ARV API business over the past nine
Operational De-leverage and Margin Pressure
The company experienced ongoing operational de-leverage, impacting margins. For Q3, EBITDA margins were reported at
LAURUSLABS Forecasts
Price
Revenue
Earnings
LAURUSLABS Share Price Forecast
All values in ₹
All values in ₹
LAURUSLABS Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
LAURUSLABS Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
LAURUSLABS
Income
Balance Sheet
Cash Flow
LAURUSLABS Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 1,781.94 | 1,937.03 | 2,085.36 | 2,308.07 | 2,837.64 | 4,837.17 | 4,950.87 | 6,046.55 | 5,067.17 | 5,308.39 | ||||||||||
Raw Materials | 1,033.24 | 1,031.67 | 1,088.41 | 1,267.63 | 1,629.55 | 2,455.20 | 2,414.94 | 2,752.28 | 2,533.30 | 4,397.16 | ||||||||||
Power & Fuel Cost | 57.96 | 66.27 | 94.21 | 109.37 | 136.77 | 157.75 | 204.47 | 324.10 | 338.15 | |||||||||||
Employee Cost | 175.46 | 204.73 | 238.14 | 276.33 | 320.77 | 397.04 | 469.55 | 557.43 | 614.85 | |||||||||||
Selling & Administrative Expenses | 67.97 | 92.25 | 96.07 | 140.99 | 189.38 | 239.88 | 276.15 | 291.01 | 335.07 | |||||||||||
Operating & Other expenses | 80.75 | 102.10 | 126.03 | 141.61 | -9.30 | 12.96 | 148.03 | 523.54 | 441.96 | |||||||||||
EBITDA | 366.56 | 440.01 | 442.50 | 372.14 | 570.47 | 1,574.34 | 1,437.73 | 1,598.19 | 803.84 | 911.23 | ||||||||||
Depreciation/Amortization | 86.41 | 105.98 | 125.45 | 164.19 | 187.27 | 205.07 | 251.49 | 324.08 | 384.58 | 421.91 | ||||||||||
PBIT | 280.15 | 334.03 | 317.05 | 207.95 | 383.20 | 1,369.27 | 1,186.24 | 1,274.11 | 419.26 | 489.32 | ||||||||||
Interest & Other Items | 111.11 | 99.90 | 79.64 | 88.19 | 89.59 | 68.16 | 102.39 | 165.17 | 182.90 | 210.10 | ||||||||||
PBT | 169.04 | 234.13 | 237.41 | 119.76 | 293.61 | 1,301.11 | 1,083.85 | 1,108.94 | 236.36 | 279.22 | ||||||||||
Taxes & Other Items | 35.30 | 43.86 | 69.81 | 25.99 | 38.34 | 317.53 | 256.33 | 318.83 | 75.81 | 78.96 | ||||||||||
Net Income | 133.74 | 190.27 | 167.60 | 93.77 | 255.27 | 983.58 | 827.52 | 790.11 | 160.55 | 200.26 | ||||||||||
EPS | 0.86 | 1.81 | 3.17 | 1.77 | 4.79 | 18.36 | 15.41 | 14.69 | 2.98 | 3.72 | ||||||||||
DPS | 0.10 | 0.30 | 0.30 | 0.30 | 0.50 | 2.00 | 2.00 | 2.00 | 0.80 | 0.80 | ||||||||||
Payout ratio | 0.12 | 0.17 | 0.09 | 0.17 | 0.10 | 0.11 | 0.13 | 0.14 | 0.27 | 0.22 |
LAURUSLABS Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
LAURUSLABS Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Laurus Labs Ltd | 210.44 | 8.21 | 0.13% |
Sun Pharmaceutical Industries Ltd | 43.78 | 6.25 | 0.77% |
Cipla Ltd | 29.62 | 4.55 | 0.86% |
Torrent Pharmaceuticals Ltd | 66.34 | 16.03 | 0.86% |
LAURUSLABS Stock Price Comparison
Compare LAURUSLABS with any stock or ETFLAURUSLABS Shareholdings
LAURUSLABS Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
LAURUSLABS Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
LAURUSLABS Shareholding Pattern
LAURUSLABS Shareholding History
Mutual Funds Invested in LAURUSLABS
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Laurus Labs Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0167% | Percentage of the fund’s portfolio invested in the stock 1.17% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 56/87 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4027% | Percentage of the fund’s portfolio invested in the stock 4.51% | Change in the portfolio weight of the stock over the last 3 months 1.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/34 (+5) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.3844% | Percentage of the fund’s portfolio invested in the stock 0.57% | Change in the portfolio weight of the stock over the last 3 months 0.36% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 79/137 (-6) |
Compare 3-month MF holding change on Screener
smallcases containing LAURUSLABS stock
Looks like this stock is not in any smallcase yet.
LAURUSLABS Events
LAURUSLABS Dividend Trend
LAURUSLABS has shown inconsistent dividend trend over the last 5 years
Current dividend yield is 0.13%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.28 every year
Dividends
Corp. Actions
Announcements
Legal Orders
LAURUSLABS Upcoming Dividends
No upcoming dividends are available
LAURUSLABS Past Dividends
Cash Dividend
Ex DateEx DateNov 6, 2024
Dividend/Share
₹0.40
Ex DateEx Date
Nov 6, 2024
Cash Dividend
Ex DateEx DateMay 8, 2024
Dividend/Share
₹0.40
Ex DateEx Date
May 8, 2024
Cash Dividend
Ex DateEx DateNov 2, 2023
Dividend/Share
₹0.40
Ex DateEx Date
Nov 2, 2023
Cash Dividend
Ex DateEx DateMay 10, 2023
Dividend/Share
₹1.20
Ex DateEx Date
May 10, 2023
Cash Dividend
Ex DateEx DateNov 3, 2022
Dividend/Share
₹0.80
Ex DateEx Date
Nov 3, 2022
LAURUSLABS Stock News & Opinions
Laurus Labs will hold a meeting of the Board of Directors of the Company on 24 April 2025.Powered by Capital Market - Live
The strategic move will enable Laurus Labs to access 25.53 MW of renewable wind and solar energy, which aligns with regulatory requirements under Indian Electricity Laws and government policies for captive consumption of power. The investment is aimed at reducing electricity costs, ensuring a reliable green power supply, and obtaining carbon credits, thus contributing to the company's environmental, social, and governance (ESG) objectives. Kurnool Renewables is engaged in the production of renewable energy, primarily from solar and wind sources. Laurus Labs' investment will support the development of the renewable power project, which will be used for captive consumption. This acquisition is expected to provide benefits such as reduced energy costs, enhanced energy security, and increased operational stability along with potential environmental advantages. The equity shares will be subscribed at an issue price determined by Kurnool Renewables, with a total investment of up to Rs 35 crore. The payment will be made in cash in three stages: 30% within 30 days from the execution of agreements, 40% upon placing orders for major equipment, and the remaining 30% upon receipt of major equipment at the project site. The acquisition does not fall within the purview of a related party transaction. In addition, Laurus Labs' board has approved the re-appointment of V.V. Ravi Kumar as the Executive Director and Chief Financial Officer (CFO) of the company for a period of two years, effective from 1 April 2025, subject to shareholder approval. V. V. Ravi Kumar is the executive director and chief financial officer of Laurus Labs Limited, bringing over three decades of rich experience, and especially two decades in Laurus itself, in finance, strategy, and corporate leadership. A qualified cost accountant from the Institute of Cost and Works Accountants of India, he plays a pivotal role in steering Laurus Labs toward sustainable growth and excellence. As a key leader at Laurus Labs, Mr. Ravi Kumar oversees critical business functions, including finance, information technology, mergers & acquisitions, strategic alliances, human resources, etc. He does not have any inter-se relationship with other directors of the company. The board also approved the re-appointment of Dr. Satyanarayana Chava as executive director and CEO for five years, starting 1, April 2025, subject to shareholder approval. Dr. Chava, the founder and CEO of Laurus Labs, has more than 30 years of experience in the pharmaceutical industry, with around 20 years at Laurus Labs. He holds a Ph.D. in chemistry from Andhra University and has been instrumental in positioning the company as a leader in both domestic and international markets. Dr. Satyanarayana Chava is the father of Mr. Krishna Chaitanya Chava and Mrs. Soumya Chava, executive directors of the company. Laurus Labs is a fully integrated pharmaceutical and biotechnology company with a leadership position in generic active pharmaceutical ingredients (APIs) and a major focus on anti-retroviral and oncology drugs, cardiovascular, gastro, and hepatitis C therapeutics. The company also develops and manufactures oral solid formulations and provides contract research and manufacturing services (CRAMS) to global pharma companies. The company's consolidated net profit soared 298.9% to Rs 92.30 crore in Q3 FY25 as against Rs 23.14 crore posted in Q3 FY24. Net sales jumped 18.4% YoY to Rs 1,415.05 crore in the quarter ended 31 December. The counter shed 0.76% to Rs 613.50 on the BSE. Powered by Capital Market - Live
The Board of Laurus Labs at its meeting held on 06 March 2025 has approved investment of an amount of Rs 83.30 crore in KRKA Pharma (KRKA), a joint venture of the Company. Further, KRKA d.d., Novo mesto, Slovenia (co-venturer) shall also invest an amount of Rs 86.70 crore in KRKA. Thereby, maintaining the existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs. The purpose of this investment is to acquire land and to meet initial cost of setting up of a manufacturing facility for production of finished products for the new markets, including the Indian market. This investment aligns with the company's strategic growth plans and long-term business objectives. Powered by Capital Market - Live
Laurus Labs Ltd rose for a third straight session today. The stock is quoting at Rs 564.2, up 3.43% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.3% on the day, quoting at 22369.85. The Sensex is at 73855.47, up 1.19%. Laurus Labs Ltd has dropped around 11.4% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has dropped around 9.06% in last one month and is currently quoting at 19820.65, up 0.98% on the day. The volume in the stock stood at 18.59 lakh shares today, compared to the daily average of 27.02 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 565.1, up 3.1% on the day. Laurus Labs Ltd is up 37.39% in last one year as compared to a 0.46% fall in NIFTY and a 4.57% fall in the Nifty Pharma index.The PE of the stock is 117.78 based on TTM earnings ending December 24.Powered by Capital Market - Live
Laurus Labs Ltd is down for a fifth straight session today. The stock is quoting at Rs 546.75, down 9.03% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.87% on the day, quoting at 22830.85. The Sensex is at 75660.79, down 0.63%.Laurus Labs Ltd has lost around 1.82% in last one month.Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has eased around 5.47% in last one month and is currently quoting at 21427.1, down 3.06% on the day. The volume in the stock stood at 48.57 lakh shares today, compared to the daily average of 44.71 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 546.25, down 9.02% on the day. Laurus Labs Ltd jumped 39.28% in last one year as compared to a 4.2% rally in NIFTY and a 11.87% spurt in the Nifty Pharma index.The PE of the stock is 129.77 based on TTM earnings ending December 24.Powered by Capital Market - Live
Laurus Labs Ltd is up for a third straight session today. The stock is quoting at Rs 638.45, up 1.16% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.41% on the day, quoting at 23600.05. The Sensex is at 77920.62, down 0.45%. Laurus Labs Ltd has gained around 4.25% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has gained around 5.07% in last one month and is currently quoting at 21868.5, up 0.83% on the day. The volume in the stock stood at 18.29 lakh shares today, compared to the daily average of 42.52 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 639.8, up 1.03% on the day. Laurus Labs Ltd is up 60.15% in last one year as compared to a 7.61% jump in NIFTY and a 18.78% jump in the Nifty Pharma index.The PE of the stock is 136.31 based on TTM earnings ending December 24.Powered by Capital Market - Live
Net profit of Laurus Labs rose 298.88% to Rs 92.30 crore in the quarter ended December 2024 as against Rs 23.14 crore during the previous quarter ended December 2023. Sales rose 18.42% to Rs 1415.05 crore in the quarter ended December 2024 as against Rs 1194.92 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1415.051194.92 18 OPM %20.1515.18 - PBDT236.77133.03 78 PBT130.6834.62 277 NP92.3023.14 299 Powered by Capital Market - Live
Laurus Labs Ltd is up for a third straight session in a row. The stock is quoting at Rs 585.45, up 3.11% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.64% on the day, quoting at 23350.8. The Sensex is at 77182.56, up 0.74%. Laurus Labs Ltd has added around 3.42% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 1.96% in last one month and is currently quoting at 22061.7, up 0.31% on the day. The volume in the stock stood at 9.9 lakh shares today, compared to the daily average of 18.42 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 585.1, up 2.72% on the day. Laurus Labs Ltd is up 46.75% in last one year as compared to a 9.94% gain in NIFTY and a 26.31% gain in the Nifty Pharma index.The PE of the stock is 130.29 based on TTM earnings ending September 24.Powered by Capital Market - Live
Laurus Labs will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live
Laurus Labs Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 590.25, up 0.61% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.03% on the day, quoting at 23805.25. The Sensex is at 78760.73, up 0.08%. Laurus Labs Ltd has added around 2.33% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 3.28% in last one month and is currently quoting at 23008.35, up 0.77% on the day. The volume in the stock stood at 16.64 lakh shares today, compared to the daily average of 19.78 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 593.15, up 0.61% on the day. Laurus Labs Ltd is up 36.3% in last one year as compared to a 9.49% gain in NIFTY and a 37.53% gain in the Nifty Pharma index.The PE of the stock is 134.5 based on TTM earnings ending September 24.Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 17.03%, vs industry avg of 9.04%
Over the last 5 years, market share increased from 1.05% to 1.33%
Over the last 5 years, net income has grown at a yearly rate of 11.35%, vs industry avg of 15.28%